Abstract
P-glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by extruding a wide range of substrates from the brain. This is important for maintaining loco-regional homeostasis and for protecting the brain against blood-borne toxic substances. Altered P-gp function seems to be involved in the pathophysiology of neurodegenerative disease and various neurological and psychiatric disorders. Positron emission tomography (PET) with the radiotracer 11C-verapamil (VPM-PET) is a validated technique allowing measurement of P-gp function at the human BBB. In this review, we highlight changes of P-gp function, as measured with VPM-PET, in aging and in the pathogenesis and progression of neurodegenerative disease, as well as their role in depressive disorders.
Keywords: P-glycoprotein, Blood-Brain Barrier, Ageing, Depression, Parkinson's Disease, Alzheimer's Disease, Positron Emission Tomography (PET), Verapamil, C-verapamil, P-glycoprotein (P-gp), Blood-brain barrier (BBB), (MRP), Central nervous system (CNS), Amyotrophic lateral sclerosis, Single-photon emission computed tomography, Tariquidar, P-gp expression, CD4+ and CD8+ T Cells, Statistical parametric mapping (SPM), Neurodegenerative disease, β-amyloid, ß-amyloid precursor protein (APP), ß-site APP cleaving enzyme (BACE), Lipoprotein receptor related protein 1 (LRP1), Cerebral amyloid angiopathy (CAA), P-gp inhibitor, Rifampicin, GSK188909, α-synuclein oligomers, C3435T TT polymorphism, Progressive supranuclear palsy (PSP), Multisystem atrophy (MSA), Pergolide, pramipexol, budipine, Huntington disease (HD), Creutzfeldt-Jakob Disease (CJD), Amyotrophic lateral sclerosis (ALS), Major depressive disorder (MDD)
Current Topics in Medicinal Chemistry
Title: 11C-verapamil to Assess P-gp Function in Human Brain During Aging,Depression and Neurodegenerative Disease
Volume: 10 Issue: 17
Author(s): A. L. Bartels, O. L. de Klerk, R. Kortekaas, J. J. de Vries and K. L. Leenders
Affiliation:
Keywords: P-glycoprotein, Blood-Brain Barrier, Ageing, Depression, Parkinson's Disease, Alzheimer's Disease, Positron Emission Tomography (PET), Verapamil, C-verapamil, P-glycoprotein (P-gp), Blood-brain barrier (BBB), (MRP), Central nervous system (CNS), Amyotrophic lateral sclerosis, Single-photon emission computed tomography, Tariquidar, P-gp expression, CD4+ and CD8+ T Cells, Statistical parametric mapping (SPM), Neurodegenerative disease, β-amyloid, ß-amyloid precursor protein (APP), ß-site APP cleaving enzyme (BACE), Lipoprotein receptor related protein 1 (LRP1), Cerebral amyloid angiopathy (CAA), P-gp inhibitor, Rifampicin, GSK188909, α-synuclein oligomers, C3435T TT polymorphism, Progressive supranuclear palsy (PSP), Multisystem atrophy (MSA), Pergolide, pramipexol, budipine, Huntington disease (HD), Creutzfeldt-Jakob Disease (CJD), Amyotrophic lateral sclerosis (ALS), Major depressive disorder (MDD)
Abstract: P-glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by extruding a wide range of substrates from the brain. This is important for maintaining loco-regional homeostasis and for protecting the brain against blood-borne toxic substances. Altered P-gp function seems to be involved in the pathophysiology of neurodegenerative disease and various neurological and psychiatric disorders. Positron emission tomography (PET) with the radiotracer 11C-verapamil (VPM-PET) is a validated technique allowing measurement of P-gp function at the human BBB. In this review, we highlight changes of P-gp function, as measured with VPM-PET, in aging and in the pathogenesis and progression of neurodegenerative disease, as well as their role in depressive disorders.
Export Options
About this article
Cite this article as:
L. Bartels A., L. de Klerk O., Kortekaas R., J. de Vries J. and L. Leenders K., 11C-verapamil to Assess P-gp Function in Human Brain During Aging,Depression and Neurodegenerative Disease, Current Topics in Medicinal Chemistry 2010; 10 (17) . https://dx.doi.org/10.2174/156802610792928059
DOI https://dx.doi.org/10.2174/156802610792928059 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protective Effects of Isothiocyanates against Alzheimer's Disease
Current Traditional Medicine Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets Disorders of Consciousness and Pharmaceuticals that Act on Oxygen Based Amino Acid and Monoamine Neurotransmitter Pathways of the Brain
Current Pharmaceutical Design Cholesterol, Lipids, Amyloid Beta, and Alzheimers
Current Alzheimer Research Epigenetic Repair of Terrifying Lucid Dreams by Enhanced Brain Reward Functional Connectivity and Induction of Dopaminergic Homeo - static Signaling
Current Psychopharmacology Bottom-Up Proteomics
Current Analytical Chemistry Obstacles and Opportunities for Cholinergic Drug Development in the Treatment of Cognitive Disorders
Current Pharmaceutical Design Preventive Effect of Soybean on Brain Aging and Amyloid-β Accumulation: Comprehensive Analysis of Brain Gene Expression
Recent Patents on Food, Nutrition & Agriculture Tauopathies – Focus on Changes at the Neurovascular Unit
Current Alzheimer Research Nanoparticle-Encapsulated Bryostatin-1 Activates α-Secretase and PKC Isoforms In vitro and Facilitates Acquisition and Retention of Spatial Learning in an Alzheimer's Disease Mouse Model
Current Alzheimer Research Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era
Current Cancer Drug Targets Effect of Barley Grain on Memory and Brain’s Oxidative Stress Factors in Male Rats
The Natural Products Journal Increase of EEG Alpha3/Alpha2 Power Ratio Detects Inferior Parietal Lobule Atrophy in Mild Cognitive Impairment
Current Alzheimer Research All Cognitive Systems but Speed and Visuospatial Functions Reduce the Effect of CSF Pathology on Other Systems
Current Alzheimer Research Olanzapine Does not Aggrevate Ischemic Neuronal Injury by Focal Cerebral Ischemia: A Dose Related Restriction of the Neuroprotective Effect?
Medicinal Chemistry The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
Current Cancer Drug Targets Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
CNS & Neurological Disorders - Drug Targets In Vitro and In Vivo Neuroprotective Effects of Etifoxine in β-Amyloidinduced Toxicity Models
CNS & Neurological Disorders - Drug Targets LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
Current Neuropharmacology TiO2-Nanowired Delivery of Mesenchymal Stem Cells Thwarts Diabetes- Induced Exacerbation of Brain Pathology in Heat Stroke: An Experimental Study in the Rat Using Morphological and Biochemical Approaches
CNS & Neurological Disorders - Drug Targets